Lui Chun Tat, Lam Ho, Cheung Koon Ho, Yip Sze Fai, Tsui Kwok Leung, Kam Chak Wah, Chui Ka Lung, Yam Ping Wa, Morawiec Beata, Kawecki Damian
Department of Accident and Emergency Medicine, Tuen Mun Hospital, Hong Kong.
Division of Cardiology, Department of Medicine and Geriatrics, Tuen Mun Hospital, Hong Kong.
Am J Emerg Med. 2015 Dec;33(12):1732-6. doi: 10.1016/j.ajem.2015.08.011. Epub 2015 Aug 10.
The objective of the study is to evaluate the role of copeptin in the diagnosis of acute coronary syndrome (ACS) and its role in dual-cardiac marker diagnostic strategy with troponin.
A prospective cohort study was carried out from May 2012 to October 2012.
The study was conducted at the emergency department (ED) of a public hospital in a cluster of Hong Kong.
Patients aged at least 18 years presented with chest pain to ED who have intermediate or high likelihood of ACS were included. All patients had blood taken in the ED for copeptin and troponin I. The adjudicated diagnoses of ACS were made by 2 independent physicians based on the universal definition. Diagnostic characteristics were calculated. Receiver operating characteristic curves were created. Areas under the curves were compared for copeptin, troponin I, and dual-marker strategy with copeptin and troponin I.
A total of 637 patients were recruited. Seventy-eight had been diagnosed to be ACS. The negative predictive value of copeptin for ACS was 0.881 (0.849-0.907) compared with troponin I, 0.937 (0.913-0.956). The areas under the receiver operating characteristic curves of copeptin, troponin I, and dual-marker strategy were 0.68, 0.859, and 0.880, respectively.
Addition of copeptin to troponin does not have significant improvement of the diagnostic accuracy of ACS in patients presented with chest pain.
本研究旨在评估 copeptin 在急性冠状动脉综合征(ACS)诊断中的作用及其在与肌钙蛋白联合的双心脏标志物诊断策略中的作用。
于 2012 年 5 月至 2012 年 10 月进行了一项前瞻性队列研究。
该研究在香港一组公立医院的急诊科进行。
纳入年龄至少 18 岁、因胸痛就诊于急诊科且 ACS 可能性为中度或高度的患者。所有患者均在急诊科采集血液检测 copeptin 和肌钙蛋白 I。由 2 名独立医生根据通用定义对 ACS 进行判定诊断。计算诊断特征。绘制受试者工作特征曲线。比较 copeptin、肌钙蛋白 I 以及 copeptin 和肌钙蛋白 I 的双标志物策略的曲线下面积。
共招募了 637 名患者。其中 78 例被诊断为 ACS。copeptin 对 ACS 的阴性预测值为 0.881(0.849 - 0.907),而肌钙蛋白 I 为 0.937(0.913 - 0.956)。copeptin、肌钙蛋白 I 和双标志物策略的受试者工作特征曲线下面积分别为 0.68、0.859 和 0.880。
在肌钙蛋白检测中加入 copeptin 对胸痛患者 ACS 的诊断准确性没有显著提高。